How Seres CEO Roger Pomerantz went from an infectious disease doctor to mining the microbiome for drugs.
In the 2015-16 flu season, more than 145 million doses were distributed by manufacturers, according to the Centers for Disease Control and Prevention, but only 41% of American adults received a vaccine.
Even as Gilead prepares to launch a third hepatitis-C product, drugs offering better antimicrobial resistance are angling for their own moments in the spotlight.
The goal is to develop medications that move beyond the high-toxicity and low-efficacy profiles of older drugs.
The Medicines Company's commercial lead for infection disease care talks about its breakthrough antidote for carbapenem-resistant enterobacteriaceae.